Cell line · CVCL_0168
Papers106
1 to 20 of 106
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting oxidative phosphorylation with lixumistat overcomes PARP inhibitor resistance in ovarian cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sinensetin Induces Oxidative Stress-Mediated Apoptosis in Non-Small Cell Lung Cancer Cells by Suppressing Nrf2/ARE-Dependent Antioxidant Defense. | J Biochem Mol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Assessing the Mutational Consequences of Chronic Arsenic Exposure Using Patient-Derived Tumor Samples and In Vitro Systems. | Environ Mol Mutagen | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Punicalin targets RSV glycoprotein and fusion protein at non-overlapping sites to prevent viral escape. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Waterpipe smoke condensate activates autophagy in non-tumorigenic lung epithelial cells: Implications for inflammation and stemness. | PLoS One | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E3 ubiquitin ligase MAGI3‑mediated TAZ ubiquitination suppresses the non‑small cell lung cancer occurrence and development by targeting the Wnt pathway. | Int J Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K. | NPJ Vaccines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell and Bulk Transcriptomic Integration Reveals an Adverse SPP1 Inflammatory TAM State and INHBA as a Candidate Biomarker in Non-Small Cell Lung Cancer Immunotherapy. | Int J Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fstl1 determines luminal size of mouse trachea through negative regulation of BMP4 signaling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine learning prioritization identifies PANX1 as an inflammation-associated candidate regulator in lung adenocarcinoma. | Front Genet | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A USP15/KRT17-associated 13-gene prognostic cluster and functional validation in EGFR-mutant lung adenocarcinoma. | Respir Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal LINC00323 accelerates angiogenesis through activating the MAPK and JAK-STAT pathways by stabilizing CDC5L in NSCLC. | Cell Oncol (Dordr) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PCK2-Mediated PQBP1 Lactylation Promotes Asthmatic Inflammation through PRMT5 Inhibition. | Research (Wash D C) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hyaluronic acid and folic acid-modified mesoporous silica nanoparticles delivering sulforaphane suppress NSCLC via SPI1/miR-616-5p axis. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0168/papers